These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 21480325)

  • 1. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
    Kida A; Mizukoshi E; Tamai T; Terashima T; Kitahara M; Arai K; Yamashita T; Fushimi K; Honda M; Kaneko S
    Liver Int; 2018 Nov; 38(11):2040-2050. PubMed ID: 29790264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma.
    Kaji K; Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Nakagawa H; Yamada K; Terashima T; Kitahara M; Kaneko S
    PLoS One; 2017; 12(1):e0170291. PubMed ID: 28114424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
    Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
    Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Honda M; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    J Hepatol; 2008 Dec; 49(6):946-54. PubMed ID: 18619700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
    Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
    Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
    Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
    Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
    Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
    Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy.
    Han Y; Wu Y; Yang C; Huang J; Guo Y; Liu L; Chen P; Wu D; Liu J; Li J; Zhou X; Hou J
    J Transl Med; 2017 Mar; 15(1):64. PubMed ID: 28330473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Fushimi K; Arai K; Yamashita T; Honda M; Kaneko S
    Liver Int; 2012 Nov; 32(10):1516-26. PubMed ID: 22830596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
    Hiroishi K; Eguchi J; Baba T; Shimazaki T; Ishii S; Hiraide A; Sakaki M; Doi H; Uozumi S; Omori R; Matsumura T; Yanagawa T; Ito T; Imawari M
    J Gastroenterol; 2010 Apr; 45(4):451-8. PubMed ID: 19936602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic strategies for hepatocellular carcinoma.
    Butterfield LH
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Kobayashi E; Kishi H; Muraguchi A; Kaneko S
    Cancer Lett; 2015 Aug; 364(2):98-105. PubMed ID: 25982205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to human telomerase reverse transcriptase-derived helper T cell epitopes in hepatocellular carcinoma patients.
    Kumagai M; Mizukoshi E; Tamai T; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Kaneko S
    Liver Int; 2018 Sep; 38(9):1635-1645. PubMed ID: 29405561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
    Butterfield LH; Ribas A; Meng WS; Dissette VB; Amarnani S; Vu HT; Seja E; Todd K; Glaspy JA; McBride WH; Economou JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5902-8. PubMed ID: 14676113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
    Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
    BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.